Pharmaceutical - Anti-virals, Johnson & Johnson


Popular Filters

1 to 25 of 37 results

Janssen expands accord with IPM for dapivirine in prevention of sexual transmission of HIV


Janssen R&D Ireland, a unit of US health care giant Johnson & Johnson, has expanded its collaboration…

Anti-viralsJanssenJohnson & JohnsonPharmaceuticalResearch

Positive CHMP opinion for Janssen’s simeprevir for chronic hepatitis C


US health care giant Johnson & Johnson’s European subsidiary Janssen R&D Ireland has received a positive…

Anti-viralsEuropeJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalRegulationsimeprevir

Positive new Ph III data from once-daily simeprevir presented at APASL


Encouraging new Phase III data for the once-daily protease inhibitor simeprevir (trade name Olysio in…

Anti-viralsJanssenJohnson & JohnsonMedivirOlysioPharmaceuticalResearchsimeprevir

Janssen sets up new group targeting unmet global health needs

Janssen sets up new group targeting unmet global health needs


US health care giant Johnson & Johnson’s Janssen companies are forming Janssen Global Public Health,…

Anti-viralsAntibiotics and Infectious diseasesJanssenJohnson & JohnsonPharmaceuticalResearch

J&J’s Invokana approved in Europe and Olysio cleared in USA

J&J’s Invokana approved in Europe and Olysio cleared in USA


It was a good news day for US health care giant Johnson & Johnson, with two of its Janssen subsidiaries…

Anti-viralsDiabetesEuropeInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaOlysioPharmaceuticalRegulation

AASLD meeting highlights: Gilead’s sofosbuvir, Janssen’s simeprevir and Boehringer’s faldaprevir


Among research results released at this week at the 64th Annual Meeting of the American Association for…

Anti-viralsBiotechnologyBoehringer IngelheimfaldaprevirGilead SciencesJanssenJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

AHF sues Johnson & Johnson over AIDS drug pricing

AHF sues Johnson & Johnson over AIDS drug pricing


The Washington DC, USA-based AIDS Healthcare Foundation (AHF) has filed a law suit in the Superior Court…

Anti-viralsJanssenJohnson & JohnsonLegalNorth AmericaPharmaceuticalPricing

Unanimous FDA panel backing for Janssen’s simeprevir for hep C

Unanimous FDA panel backing for Janssen’s simeprevir for hep C


Janssen announced yesterday that the FDA's Antiviral Drugs Advisory Committee unanimously recommended…

Anti-viralsJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevir

Janssen-Cilag files European approval of combination medicine for HIV-1


US health care giant Johnson & Johnson subsidiary Janssen-Cilag International NV has submitted a Marketing…

Anti-viralsBiotechnologycobicistatDarunavirEuropeGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulation

Janssen gains rights to Ph II hepatitis C candidate from GSK


Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

Janssen files for European approval of hep C candidate simeprevir


Janssen-Cilag International, a European subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ),…

Anti-viralsBiotechnologyEuropeJanssen-CilagJohnson & JohnsonPharmaceuticalRegulationsimeprevir

Highlights of presentations from Bristol-Myers, J&J, Gilead and AbbVie at EASL meeting


Among a number of drug and biotech majors planning to present at the 2013 annual meeting of the European…

AbbVieAnti-viralsasunaprevirBiotechnologyBristol-Myers SquibbdaclatasvirGilead SciencesJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

Medivir/J&J, Merck & Co and Bristol-Myers to present at Int Liver Congress


Swedish infectious disease drug developer Medivir AB (OMX: MVIR) and US partner Johnson & Johnson (NYSE:…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirJohnson & JohnsonMedivirMerck & CoMK-5172PharmaceuticalResearchsimeprevirVaniprevirVictrelis

Janssen gains FDA approval of Invokana for type 2 diabetes; files simeprevir NDA


There were a couple of good news items for Johnson & Johnson (NYSE: JNJ) unit Janssen Pharmaceuticals…

Anti-viralsDiabetesInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevirTMC435

Australia to subsidize groundbreaking hepatitis C drugs under PBS


The Australian government said on February 19 that it is extended subsidies of important medicines each…

Anti-viralsAsia-PacificFinancialHealthcareIncivoJohnson & JohnsonMerck & CoPharmaceuticalPricingVictrelis

Regulatory briefs from Astellas, Janssen, Biogen and Elan, and QRxPharma


The US subsidiary of Japanese drug major Astellas Pharma (TYO: 4503) says the US Food and Drug Administration…

Anti-viralsAstellas PharmaBiogen IdecBiotechnologyElanEuropeJanssenJohnson & JohnsonMoxDuoNeurologicalNorth AmericaOncologyPharmaceuticalPrezistaQRxPharmaRegulationTarcevaTysabri

NGM Biopharma in deal with Janssen for novel diabetes therapeutics; Microbiotix in-licenses drugs from Merck & Co


USA-based NGM Biopharmaceuticals has signed a worldwide agreement with health care giant Johnson & Johnson…

Anti-viralsDiabetesJanssenJohnson & JohnsonLicensingMBX-700MBX-701Merck & CoMetabolicsMicrobiotixNGM BiopharmaceuticalsPharmaceutical

Incivo plus peginterferon and ribavirin positive for co-infected hep C and HIV patients, says Janssen


US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Infectious Diseases - Diagnostics BVBA presented…

Anti-viralsBiotechnologyIncivoJanssenJohnson & JohnsonPharmaceuticalResearch

Vertex links with Janssen and GlaxoSmithKline for combo trials with its VX-135 for hepatitis C


US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals unit has entered into a…

Anti-viralsBiotechnologyGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonPharmaceuticalResearchsimeprevirVertexVX-135

Crucell and Scripps Research discover broad-spectrum antibodies against influenza B


In what is described as a landmark discovery, researchers from Crucell Holland, which became wholly-owned…

Anti-viralsBiotechnologyCrucellJohnson & JohnsonPharmaceuticalResearchVaccines

J&J'S rilpivirine also proven for combination HIV product, says IQWiG


Since the start of 2012, a new drug - rilpivirine from US health care giant Johnson & Johnson (NYSE:…

Anti-viralsEuropeEvipleraJohnson & JohnsonPharmaceuticalPricingRegulationrilpivirine

Janssen files for EU approval of canagliflozin in type 2 diabetes; Ferrer pulls Egrifta MAA


US health care giant Johnson & Johnson's (NYSE: JNJ) European subsidiary Janssen-Cilag International…

Anti-viralscanagliflozinDiabetesEgriftaEuropeFerrer InternacionalJanssenJohnson & JohnsonPharmaceuticalRegulation

1 to 25 of 37 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top